Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive

@inproceedings{Mckeown2009EpsteinBarrV,
  title={Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive},
  author={Emily J Mckeown and Janet Elizabeth Pope and Suzanne Leaf},
  booktitle={The open rheumatology journal},
  year={2009}
}
OBJECTIVE Anti-TNF agents (etanercept, infliximab and adalimumab) are widely used in inflammatory conditions, such as rheumatoid arthritis; however, they are not without side effects, potentially including lymphoma. We compared Epstein-Barr virus (EBV) levels in patients with inflammatory arthritis taking biologic agents and controls matched for disease, age, gender and disease duration who were biologic naïve. Secondly, we determined the risk of reactivation of EBV in patients taking biologics… CONTINUE READING
5 Citations
21 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy

  • D Reijasse, C Le Pendeven, J Cosnes
  • Inflamm Bowel Dis
  • 2004
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…